Not medical advice. Talk to your provider before using any peptide.
Full disclaimerSemaglutide vs Retatrutide
Peptide Schedule Research TeamReviewed Apr 202623 Citations
Side-by-side comparison of dosage, benefits, and side effects.
14.9% of body weight gone in 68 weeks. That number, from the STEP 1 trial (PMID 33567185, n=1,961), turned semaglutide into the most prescribed weight loss drug in modern medicine. Semaglutide (CAS 910463-68-2) is a GLP-1 receptor agonist sold as Ozempic, Wegovy, Wegovy HD, and Rybelsus. The drug mimics incretin hormone GLP-1. It binds receptors in the pancreas, the gut, and satiety centers in the hypothalamus. Pancreatic binding increases insulin secretion. Gut binding slows gastric emptying. Brain binding turns down hunger signals. An albumin-binding fatty acid side chain extends the half-life to roughly 7 days, allowing once-weekly dosing. Real-world use spans three FDA indications. Obesity patients follow the Wegovy titration from 0.25 mg up to 2.4 mg weekly (or 7.2 mg with the high-dose label approved March 2026). Type 2 diabetics typically land between 0.5 and 2.0 mg weekly on the Ozempic label. Cardiovascular patients stay at 2.4 mg long-term after SELECT (PMID 37952131) confirmed a 20% reduction in major adverse cardiovascular events across 17,604 participants. Community experience tracks the clinical data closely. Over 350,000 combined members across r/Ozempic and r/semaglutide consistently report appetite suppression, steady 1 to 2 lbs per week weight loss, and reduced food noise within the first month. The honest caveat: two-thirds of the weight returns within a year of stopping (STEP 1 extension data). Lean mass loss of 25 to 40% without resistance training is well-documented. This is a long-term commitment, not a quick fix. In SURMOUNT-5 (PMID 40353578, n=751), semaglutide 2.4 mg produced 13.7% weight loss versus 20.2% for tirzepatide 15 mg at 72 weeks. Semaglutide holds the stronger cardiovascular outcomes dataset: the SELECT trial (PMID 37952131, n=17,604) confirmed a 20% reduction in major adverse cardiovascular events over 39.8 months.
View full guide →28.7% mean body weight gone in 68 weeks. That Phase 3 number from TRIUMPH-4 (n=445, December 2025) set a new ceiling for obesity pharmacotherapy. No other drug, approved or investigational, has matched it. The retatrutide peptide (LY3437943, CAS 2381089-83-2) is a 44-amino-acid synthetic lipopeptide developed by Eli Lilly. Known in community forums as reta peptide or Triple G, it activates GLP-1, GIP, and glucagon receptors simultaneously in a single molecule. The GLP-1 component suppresses appetite and slows gastric emptying. GIP improves insulin response and buffers GLP-1 tolerability. Glucagon raises resting energy expenditure and burns liver fat directly. That third receptor is the differentiator; dual agonists like tirzepatide lack it entirely. Clinicians and researchers tracking the obesity pharmacotherapy space have been watching retatrutide since the Phase 2 readout (Jastreboff et al., NEJM 2023, PMID 37366315), where 338 adults lost up to 24.2% body weight at 48 weeks on the 12 mg dose. A separate Phase 2a MASLD trial (Nature Medicine 2024, PMID 38858523) showed 82.4% relative liver fat reduction in 98 participants at 24 weeks. Seven more Phase 3 TRIUMPH trials are still reading out. Community users who plateaued on semaglutide or tirzepatide have driven early adoption through compounding pharmacies. The enthusiasm is high; so are the GI side effects during dose escalation. NDA submission is expected in late 2026 or early 2027. Until then, retatrutide carries no FDA approval and no insurance coverage.
View full guide →At a Glance
| Attribute |  Semaglutide |  Retatrutide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| Safety Grade | A | B |
| Half-Life | ~7 days | ~6 days |
| Route | Subcutaneous | Subcutaneous |
| Vial Sizes | 5mg, 10mg | 5mg, 10mg, 15mg |
| Beginner Dose | 250mcg Weekly | 1000mcg Weekly |
| Moderate Dose | 500mcg Weekly | 4000mcg Weekly |
| Aggressive Dose | 1000mcg Weekly | 8000mcg Weekly |
| Dosing Source | FDA Label | Clinical Trial |
| Side Effects | Black box warning: semaglutide causes thyroid C-cell tumors in rodents. Whether it causes medullary thyroid carcinoma in humans is unknown. Anyone with a personal or family history of MTC or MEN2 cannot use this drug. That warning is printed on every Wegovy and Ozempic label, and it stays there. GI side effects dominate the titration period. Nausea hits 40 to 50% of patients during the first weeks at each new dose level. For some, that nausea is severe enough to impact daily function and work productivity. Community consensus recommends extending each titration step to 6 to 8 weeks rather than 4 if nausea is bad. The nausea typically fades within the first week at each stable dose. Constipation affects the majority of long-term users. Proactive fiber supplementation (psyllium husk from day one) is the top community recommendation. Magnesium citrate at 200 to 400 mg before bed serves as the standard backup. Vomiting and diarrhea also occur, usually transiently during dose escalation. Rare but serious: pancreatitis requires immediate emergency evaluation if you experience severe abdominal pain radiating to the back. Gallbladder disease (cholelithiasis, cholecystitis) is a known complication, particularly with rapid weight loss. Acute kidney injury can result from dehydration driven by persistent GI symptoms. FDA postmarketing warnings from September 2023 flagged three additional signals. Ileus (intestinal obstruction) requires emergency care if you develop severe persistent abdominal pain. Diabetic retinopathy complications can paradoxically worsen with rapid A1c improvement in patients with pre-existing retinopathy. Resting heart rate increases a mean 1 to 4 bpm; 26% of SELECT participants had increases of 20 bpm or more. The 7.2 mg Wegovy HD dose introduced a new signal: dysesthesia (tingling, numbness) in 18.9% of patients vs. 0% on placebo in STEP UP. That adverse event profile is still being characterized. Hair thinning from telogen effluvium peaks between months 3 and 6. It is a response to rapid weight loss, not a direct drug effect. It typically resolves by month 8 to 12 with adequate protein intake. Lean mass loss of 25 to 40% of total weight lost is documented without resistance training. "Ozempic face" (facial volume loss) becomes visible after 30+ lbs of weight loss. Contraindications: personal or family history of MTC or MEN2, history of pancreatitis, pregnancy or breastfeeding, hypersensitivity to semaglutide, severe gastrointestinal disease including gastroparesis. If you are on insulin or sulfonylureas, doses of those drugs typically need a 20 to 30% reduction at semaglutide initiation to prevent hypoglycemia. | Gastrointestinal events during dose escalation are the defining tolerability challenge with retatrutide, and they hit harder than comparable GLP-1 agents at equivalent titration speeds. In TRIUMPH-4 Phase 3 data (PMID 40291085), nausea occurred in 38 to 43% of participants. Diarrhea affected 33 to 35%. Constipation hit 22 to 25%. Vomiting was reported in 21%. These rates are dose-dependent and front-loaded, meaning they peak during the weeks immediately after each dose increase. Most GI events resolve within 1 to 2 weeks at a stable dose. Slow titration from 1 mg with 4-week steps between escalations reduces severity substantially. Raised resting heart rate is the second signal that deserves attention. Phase 2 trials (PMID 37366315) documented a dose-dependent increase in resting HR tied to glucagon receptor activation. Community users at 8 mg and above have reported palpitations and sustained HR above 90 bpm. Phase 3 data suggests this effect is manageable with proper monitoring, but anyone with a cardiac history should track heart rate weekly during titration. Do not escalate if resting HR stays above 100 bpm. Post-injection fatigue, sometimes called "wipeout day," shows up consistently in community reports at doses of 8 mg or higher. Users describe pronounced fatigue lasting 12 to 24 hours after injection, particularly during the first 2 to 4 weeks at a new dose level. Scheduling the injection on a low-demand day helps. The GLP-1 class carries an unresolved rodent thyroid C-cell tumor signal. No confirmed human thyroid cancer risk has been established for any GLP-1 agonist, but retatrutide is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Pancreatitis is a known class risk. Severe persistent abdominal pain radiating to the back warrants immediate medical attention and discontinuation. Pregnancy is an absolute contraindication. No reproductive toxicity data exist for retatrutide. Discontinue well before any planned pregnancy. Product quality adds a layer of risk specific to investigational peptides. Retatrutide is not FDA approved; compounded versions lack standardized formulation. Request a Certificate of Analysis with HPLC purity data for every batch. Grey-market research chemicals carry contamination and identity risks that cannot be verified. |
Key Differences
- Semaglutide targets GLP-1 only; Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors.
- Retatrutide showed up to 24% body weight loss in Phase 2 trials: the highest of any peptide to date.
- Semaglutide is FDA-approved and widely available; Retatrutide is still in clinical trials.
- Retatrutide's glucagon component may offer additional benefits for liver fat reduction.
When to Choose Semaglutide
- You want an FDA-approved, well-established option
- You want more long-term safety data available
- Accessibility and availability are priorities
- You're achieving adequate results with single GLP-1 therapy
When to Choose Retatrutide
- You want the most aggressive weight loss potential available
- You haven't responded well to single or dual agonists
- Liver fat reduction is an additional goal
- You're comfortable with a newer, less-studied peptide
Can You Stack Semaglutide + Retatrutide?
These should not be stacked as they share GLP-1 activity. Retatrutide already includes GLP-1 agonism.
Dosage Calculators
Or use the universal Peptide Calculator for any peptide.